LY 4066434
Alternative Names: LY-4066434Latest Information Update: 24 Jun 2025
At a glance
- Originator Loxo Oncology
- Class Antineoplastics; Small molecules
- Mechanism of Action KRAS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 25 Apr 2025 Pharmacodynamics data from a preclinical trial in Solid tumours presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 10 Oct 2024 Phase-I clinical trials in Solid tumours (Metastatic disease, Late-stage disease, Inoperable/Unresectable, Combination therapy) in USA (PO) (NCT06607185)
- 10 Oct 2024 Phase-I clinical trials in Solid tumours (Metastatic disease, Late-stage disease, Inoperable/Unresectable, Monotherapy) in USA (PO) (NCT06607185)